Cryoport, the leading provider of advanced cryogenic solutions for the life sciences industry, announced on July 30th that it will offer cryogenic logistics solutions to HemaCare. Under this agreement, Cryoport will deliver cold chain logistics for a wide range of cell and tissue samples that can be applied to advanced biomedical research, cell therapy-based clinical trials, and product commercialization.
Cryoport is foremost in offering logistics to cell and tissue samples for use in fields in which many HemaCare's customers are well-versed, including immunotherapies, CAR T cells, stem cells, cell lines, and vaccines, to name a few. Cryoport’s validated and comprehensive cryogenic logistics solutions will be there to help guarantee that the integrity of the shipment is maintained throughout the entire process. As Pete van der Wal, President and CEO of HemaCare, explains:
“Maintaining the quality and integrity of our products is an essential component to achieving favorable research outcomes, and something our customers have come to expect from us. Cryoport’s shared commitment to quality and reputation for the highest packaging and shipping standards ensures that our products are delivered without significant loss of viable, functional cells.”